GlassScriptPhysician profile
Debanshu Roy
NPI 1992125751
$17,260.64
in general payments reported to CMS, 2019-2025
14 companies · $195 in 2025
The $195 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $149 · 2020: $15K · 2021: $726 · 2022: $402 · 2023: $20.03 · 2024: $384 · 2025: $195.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $599.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $15,187.13 | 2019-2020 | |
| Abiomed | $670.79 | 2020-2025 | Impella |
| Abbott Laboratories | $448.13 | 2019-2022 | |
| Medtronic, INC. | $275.68 | 2021-2022 | |
| Edwards Lifesciences Corporation | $147.22 | 2020-2021 | |
| E.R. Squibb & Sons, L.L.C. | $121.20 | 2025 | Camzyos |
| Amarin Pharma, INC. | $119.66 | 2022 | |
| Chiesi USA, INC. | $75.13 | 2021 | |
| Ekos Corporation | $64.94 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $46.35 | 2023-2024 | Lifevest |
| Novartis Pharmaceuticals Corporation | $32.15 | 2022-2024 | |
| Shockwave Medical, INC | $27.95 | 2022 | |
| United Therapeutics Corporation | $22.27 | 2019 | |
| Teleflex LLC | $22.04 | 2025 | Manta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debanshu Roy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.